Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) EBT Margin (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EBT Margin for 2 consecutive years, with 43.4% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 15956.0% to 43.4% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.08% through Dec 2025, up 8155.0% year-over-year, with the annual reading at 69.1% for FY2025, 173.0% down from the prior year.
  • EBT Margin for Q4 2025 was 43.4% at Day One Biopharmaceuticals, up from 49.48% in the prior quarter.
  • The five-year high for EBT Margin was 37.28% in Q3 2024, with the low at 1353.09% in Q2 2024.